Michael is the chair of our board of directors. He is also the chair of the board of Pulmatrix, Inc. and a board member at Genocea Biosciences, Nocion Therapeutics, Camp4 Therapeutics and Sea Pharmaceuticals. Previously, Michael served as entrepreneur-in-residence at Polaris Partners, senior vice president and chief operating officer of Ironwood Pharmaceuticals Inc., and held a variety of senior business positions at Genzyme Corporation, including vice president of Corporate Finance and vice president of Business Development. Prior to joining Genzyme Corporation, he led Procept, Inc.’s financial team. Michael has a B.S. from Cornell University and an M.B.A. from the Amos Tuck School of Business Administration at Dartmouth College.
Jim serves as chair of the board of directors of Idera Pharmaceuticals, Orchard Therapeutics, and Pieris Pharmaceuticals, and as a director of Fulcrum Therapeutics. He was previously an entrepreneur-in-residence at Third Rock Ventures and served earlier as senior vice president Strategy and Business Development at Sanofi. Jim held wide-ranging leadership positions at Genzyme, including senior vice president International Development, president of Genzyme Europe, general manager Cardiovascular, and chair and chief executive officer of Genzyme Transgenics. Jim started his career at Bain & Company. He has a B.A. from Georgetown, an M.S. from the University of Pennsylvania, and a J.D. from Yale.
Steve serves as director of the Stanley Center for Psychiatric Research at the Broad Institute of Harvard and MIT and as a core faculty member of the Broad Institute. He also serves as a Harvard University Distinguished Service Professor of Stem Cell and Regenerative Biology and has previously served as provost of Harvard University, the university’s chief academic officer. Steve has held various additional roles including as director of the U.S. National Institute of Mental Health, the editor-in chief of the Annual Review of Neuroscience, and president of the Society for Neuroscience. He was elected to the Institute of Medicine, renamed the National Academy of Medicine, where he served on the governing Council, the board of Health Science Policy, and chaired the Forum on Neuroscience and Nervous System Disorders, and he was founding president of the International Neuroethics Society, a fellow of the American Academy of Arts and Sciences, a fellow of the American Association for the Advancement of Science, a fellow of the American College of Neuropsychopharmacology (President 2018) and a Distinguished Life Fellow of the American Psychiatric Association. Steve received a B.A. from Yale College, an M.A. from the University of Cambridge, which he attended as a Mellon fellow, and an M.D. from Harvard Medical School.
Mark is a co-founder and partner at Third Rock Ventures. Previously, Mark served as chief executive officer of Millennium Pharmaceuticals for 12 years. Earlier in his career, Mark was co-founder of Mayfield Fund’s life sciences effort and an engineer and project leader at Eli Lilly and Genentech. He is a member of the National Academy of Engineering and the Friends of Personalized Medicine, and he co-founded the Possible Project in Cambridge, Mass. Mark holds a B.S. and M.S. in chemical and biochemical engineering from Washington University.
Andre serves as our president and chief executive officer. Prior to joining Voyager, Andre held a variety of leadership positions at Genzyme and Sanofi. He most recently served as Sanofi’s senior vice president and global head of Business Development & Licensing and chair of the Sanofi Transaction Committee. He previously served as Genzyme’s global head of Strategy and Business Development, general manager of Sanofi Genzyme Australia/New Zealand and head of Commercial Operations for the Renal and Endocrinology division. Andre began his career in the industry as a consultant at Kendall Strategies, a boutique healthcare consulting firm. Andre has a B.A. from Kalamazoo College and an M.B.A. from the Tuck School of Business at Dartmouth.
Steve serves as the chief executive officer and chair of the board of Karuna Therapeutics. Prior to Karuna, he served as Voyager’s president and chief executive officer. Additionally, he is a venture partner at Third Rock Ventures. Before joining Voyager, Steve was the founding director of the Appel Alzheimer’s Disease Research Institute, as well as professor of neuroscience, psychiatry and pharmacology at Weill Cornell Medical College. Preceding his appointment at Weill Cornell, Steve served in several key leadership roles at Eli Lilly, including president of the Lilly Research Laboratories, and vice president of Discovery Research and Neuroscience Research. Prior to Eli Lilly, Steve served as scientific director of the National Institute of Mental Health at NIH and as medical director in the Commissioned Corps of the United States Public Health Service. He is an elected fellow of the American Association for the Advancement of Science and a member of the National Academy of Medicine of the National Academy of Sciences. Steve also serves on the boards of Sage Therapeutics and Alnylam Pharmaceuticals, and is a chair of the board for the Foundation for the National Institutes of Health. He has authored or co-authored more than 550 papers and book chapters. Steve has a B.A. in biology and psychology from Tulane University and an M.S. and M.D. from the Tulane University School of Medicine.
Glenn serves as entrepreneur-in-residence at Third Rock Ventures. At Third Rock, he co-founded Ambys Medicines and serves as interim chief medical officer. Glenn previously served in a number of roles at Biogen, most recently as chief medical officer leading the hematology, cell and gene therapies division. Prior to Biogen, he served in small, large, public and private biotech/biopharma firms, including Bayer, Inspiration, Avigen, Selective Genetics and Amgen in the areas of tissue regeneration and hematology. Glenn is the co-author of more than 150 scientific papers and received more than 15 patents. He served on the medical and scientific advisory council, the board of directors and was president of the board of the National Hemophilia Foundation. Glenn also served on the Blood Products Advisory Committee at the FDA and the Committee on Blood Safety and Availability at the U.S. Department of Health and Human Services. He currently serves on the boards of directors of Global Blood Therapeutics and the World Federation of Hemophilia as the vice president, Medical. Dr. Pierce received an M.D. and a Ph.D. in Immunology, both from Case Western Reserve University in Cleveland, and completed his postgraduate training in pathology and hematology research at Washington University in St. Louis.
Nancy is the co-founder and managing partner at Partners for Wellbeing, a boutique human resources consulting firm. Previously, Nancy served as senior vice president and chief human resource officer at Genentech, a member of the Roche Group. Prior to Genentech, Nancy held senior human resources roles at Procter & Gamble and CIGNA. She currently serves on the board of directors for the Make a Wish Foundation. Nancy has a B.B.A. from the University of Michigan and an M.B.A. from Emory University.